Aerie Pharmaceuticals Inc

Vioquest Pharmaceuticals Inc. is a biotechnology company based in Monmouth Junction, NJ, focusing on the development of innovative therapeutic solutions for autoimmune diseases. With a strong emphasis on research and preclinical development, the company is advancing its pipeline of drug candidates, including PV-3212, aimed at treating multiple sclerosis and other autoimmune conditions. The company is dedicated to exploring MHC II inhibition and developing inhibitors targeting diseases such as Goodpasture's syndrome and Parkinson's. Vioquest Pharmaceuticals also provides drug discovery services supported by expert medicinal chemistry and therapeutic expertise to facilitate client-driven projects. Generated from the website

Abeille Pharmaceuticals Inc is a research-driven company based in Princeton, NJ, specializing in the development of innovative pharmaceutical products. With a focus on cutting-edge technology and scientific advancements, Abeille Pharmaceuticals Inc is dedicated to improving healthcare outcomes for patients worldwide. Committed to excellence in drug discovery and development, Abeille Pharmaceuticals Inc collaborates with leading experts in the field to bring novel therapies to market. Through a combination of expertise and strategic partnerships, the company strives to address unmet medical needs and make a meaningful impact on global health. Generated from their business information

Jacobus Pharmaceutical Company Inc., based in Plainsboro, New Jersey, is a pharmaceutical company that specializes in the production of medications. They recently issued a voluntary worldwide recall of their product, Ruzurgi amifampridine 10 mg tablets, due to contamination with yeast, mold, and bacterial organisms. The recall was prompted by laboratory test results that revealed the presence of these contaminants, which can potentially cause serious and life-threatening infections, particularly in individuals with underlying immunosuppressive conditions. Ruzurgi amifampridine is used as a treatment for Lambert Eaton Syndrome (LEMS) in patients aged 6 to less than 17. The affected product was distributed globally to specialty pharmacies and physicians. Jacobus Pharmaceutical Company Inc. is taking immediate action to notify distributors and customers, and arrangements are being made for the return of all recalled products. Consumers who have purchased Ruzurgi amifampridine are advised to discontinue use and return the product to the company.Generated from the website